Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model.
about
A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver.What is the potential role of hepatic arterial infusion chemo-therapy in the current armamentorium against colorectal cancer.In vivo assessment of intratumoral aspirin injection to treat hepatic tumors.Postoperative prophylactic hepatic arterial infusion chemotherapy for stage III colorectal cancer: a retrospective study.Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy.Role of intra-arterial hepatic chemotherapy in the treatment of colorectal cancer metastases.Meeting the biologic challenge of colorectal metastases.Locoregional therapies for metastatic colorectal carcinoma to the liver--an evidence-based review.The state of regional therapy in the management of metastatic colorectal cancer to the liver.Treatment Options in Colorectal Liver Metastases: Hepatic Arterial Infusion.Hepatic arterial infusion of gemcitabine-oxaliplatin in a large metastasis from colon cancer.Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapyAntitumoural hydroxyapatite nanoparticles-mediated hepatoma-targeted trans-arterial embolization gene therapy: in vitro and in vivo studies.Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis.Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973)
P2860
Q33390290-CD9012AC-3332-4D87-B34B-FEFB6026BAB5Q36097254-96E56A8B-AA06-40F3-9167-CD61AE915B2AQ37049114-AE0C12B4-C446-464A-9DDC-6116A56297FFQ37301343-00E26C5B-8690-4F43-BAE6-ABBA6430556CQ37456742-0EB82BAA-E360-41D4-8E87-476FB6BB62C4Q37821853-13E6C5BF-C436-40C2-A68A-2D64C5964ABEQ38051068-8DCB5489-E53F-4146-9A23-A25DE48DE238Q38206730-5184FAAD-4E45-4E4D-8375-C25B4EDB5A58Q38664762-A61BC541-DC82-4A0E-B74E-C93E35E214CBQ39371177-FBCC3C80-CA41-420D-992B-355CAFC18A5DQ39530243-A4E0CD85-0D6E-4420-B6B8-8D0EAA5A4545Q39579889-8BA983BC-B835-40E8-B7EC-2B469C4D3DFAQ45877188-0F40F8E2-1138-4771-ACAB-C7194697D768Q48256935-90B2135A-6C46-4AC6-B37D-32D61485FC1CQ58799367-1974B16E-877E-4E87-BF7C-1085B36BEF06
P2860
Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Pharmacokinetic advantage of i ...... sing a rabbit VX2 tumor model.
@en
Pharmacokinetic advantage of i ...... sing a rabbit VX2 tumor model.
@nl
type
label
Pharmacokinetic advantage of i ...... sing a rabbit VX2 tumor model.
@en
Pharmacokinetic advantage of i ...... sing a rabbit VX2 tumor model.
@nl
prefLabel
Pharmacokinetic advantage of i ...... sing a rabbit VX2 tumor model.
@en
Pharmacokinetic advantage of i ...... sing a rabbit VX2 tumor model.
@nl
P2093
P1433
P1476
Pharmacokinetic advantage of i ...... sing a rabbit VX2 tumor model.
@en
P2093
Alain Gouyette
Gonzalo Gomez-Abuin
Jean-Nicolas Munck
Marc Bonnay
Michel Ducreux
Patrice Ardouin
Philippe Rougier
Radan Dzodic
P304
P356
10.1097/01.CAD.0000131684.06390.FE
P50
P577
2004-07-01T00:00:00Z